ASAP Act

TL;DR (AI)

• The bill provides Medicare coverage for blood-based dementia screening tests to detect Alzheimer's disease and related dementias at the pre-symptomatic and early stages.
• Covered tests must be cleared, classified, or approved under the Federal Food, Drug, and Cosmetic Act, and include genomic sequencing blood tests and other equivalent tests.
• Payment for these screening tests will be included under existing Medicare payment guidelines, with covered tests furnished on or after January 1, 2028.